Related Experiment Video

Updated: May 30, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

New anticoagulants: moving on from scientific results to clinical implementation

Elise S Eerenberg1, Josien van Es, Meertien K Sijpkens

  • 1Department of Vascular Medicine, Academic Medical Centre , Amsterdam , the Netherlands.

Annals of Medicine
|August 26, 2011
PubMed

Insights

Novel oral anticoagulants like dabigatran and rivaroxaban offer predictable effects for treating venous thromboembolism (VTE). Further research is needed to confirm their safety in diverse patient populations and clinical practice.

Area of Science:

  • Pharmacology
  • Cardiology
  • Hematology

Background:

  • Vitamin K antagonists (VKA) are the standard oral anticoagulants for venous thromboembolism (VTE).
  • VKA exhibit unpredictable anticoagulant effects, leading to risks of under- and over-treatment.
  • Novel oral anticoagulants (NOACs) present a potential alternative with more predictable anticoagulant activity.

Purpose of the Study:

  • To evaluate the efficacy and safety of novel oral anticoagulants (dabigatran and rivaroxaban) in VTE treatment and stroke prevention.
  • To compare the predictable anticoagulant effect of NOACs with Vitamin K antagonists (VKA).
  • To assess the potential challenges in translating NOACs from clinical trials to daily practice.

Main Methods:

  • Review of Phase II and III clinical studies on dabigatran and rivaroxaban.
  • Analysis of data regarding VTE prophylaxis and treatment.
  • Examination of stroke prevention in atrial fibrillation.

Main Results:

  • Phase II and III studies indicate efficacy and safety for dabigatran and rivaroxaban in VTE and atrial fibrillation.
  • NOACs demonstrate a more predictable anticoagulant effect compared to VKA.
  • Further investigation is required to confirm NOAC safety in real-world clinical settings.

Conclusions:

  • Novel oral anticoagulants show promise as replacements for Vitamin K antagonists.
  • Real-world clinical data is crucial to validate the safety and efficacy of NOACs in vulnerable patient groups.
  • Lack of established monitoring and antidote protocols may impede the clinical adoption of NOACs.

More Related Videos

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...